Literature DB >> 25393273

Genomic rearrangements in prostate cancer.

Christopher E Barbieri1, Mark A Rubin.   

Abstract

PURPOSE OF REVIEW: Genomic instability is a fundamental feature of human cancer, leading to the activation of oncogenes and inactivation of tumor suppressors. In prostate cancer (PCA), structural genomic rearrangements, resulting in gene fusions, amplifications, and deletions, are a critical mechanism effecting these alterations. Here, we review recent literature regarding the importance of genomic rearrangements in the pathogenesis of PCA and the potential impact on patient care. RECENT
FINDINGS: Next-generation sequencing has revealed a striking abundance, complexity, and heterogeneity of genomic rearrangements in PCA. These recent studies have nominated a number of processes in predisposing PCA to genomic rearrangements, including androgen-induced transcription.
SUMMARY: Structural rearrangements are the critical mechanism resulting in the characteristic genomic changes associated with PCA pathogenesis and progression. Future studies will determine whether the impact of these events on tumor phenotypes can be translated to clinical utility for patient prognosis and choices of management strategies.

Entities:  

Mesh:

Year:  2015        PMID: 25393273      PMCID: PMC4269103          DOI: 10.1097/MOU.0000000000000129

Source DB:  PubMed          Journal:  Curr Opin Urol        ISSN: 0963-0643            Impact factor:   2.309


  51 in total

1.  Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer.

Authors:  Scott A Tomlins; Daniel R Rhodes; Sven Perner; Saravana M Dhanasekaran; Rohit Mehra; Xiao-Wei Sun; Sooryanarayana Varambally; Xuhong Cao; Joelle Tchinda; Rainer Kuefer; Charles Lee; James E Montie; Rajal B Shah; Kenneth J Pienta; Mark A Rubin; Arul M Chinnaiyan
Journal:  Science       Date:  2005-10-28       Impact factor: 47.728

2.  TMPRSS2:ERG fusion-associated deletions provide insight into the heterogeneity of prostate cancer.

Authors:  Sven Perner; Francesca Demichelis; Rameen Beroukhim; Folke H Schmidt; Juan-Miguel Mosquera; Sunita Setlur; Joelle Tchinda; Scott A Tomlins; Matthias D Hofer; Kenneth G Pienta; Rainer Kuefer; Robert Vessella; Xiao-Wei Sun; Matthew Meyerson; Charles Lee; William R Sellers; Arul M Chinnaiyan; Mark A Rubin
Journal:  Cancer Res       Date:  2006-09-01       Impact factor: 12.701

3.  TMPRSS2:ERG gene fusion associated with lethal prostate cancer in a watchful waiting cohort.

Authors:  F Demichelis; K Fall; S Perner; O Andrén; F Schmidt; S R Setlur; Y Hoshida; J-M Mosquera; Y Pawitan; C Lee; H-O Adami; L A Mucci; P W Kantoff; S-O Andersson; A M Chinnaiyan; J-E Johansson; M A Rubin
Journal:  Oncogene       Date:  2007-01-22       Impact factor: 9.867

4.  TMPRSS2:ETV4 gene fusions define a third molecular subtype of prostate cancer.

Authors:  Scott A Tomlins; Rohit Mehra; Daniel R Rhodes; Lisa R Smith; Diane Roulston; Beth E Helgeson; Xuhong Cao; John T Wei; Mark A Rubin; Rajal B Shah; Arul M Chinnaiyan
Journal:  Cancer Res       Date:  2006-04-01       Impact factor: 12.701

5.  SLC45A3-ELK4 is a novel and frequent erythroblast transformation-specific fusion transcript in prostate cancer.

Authors:  David S Rickman; Dorothee Pflueger; Benjamin Moss; Vanessa E VanDoren; Chen X Chen; Alexandre de la Taille; Rainer Kuefer; Ashutosh K Tewari; Sunita R Setlur; Francesca Demichelis; Mark A Rubin
Journal:  Cancer Res       Date:  2009-03-17       Impact factor: 12.701

6.  Role of the TMPRSS2-ERG gene fusion in prostate cancer.

Authors:  Scott A Tomlins; Bharathi Laxman; Sooryanarayana Varambally; Xuhong Cao; Jindan Yu; Beth E Helgeson; Qi Cao; John R Prensner; Mark A Rubin; Rajal B Shah; Rohit Mehra; Arul M Chinnaiyan
Journal:  Neoplasia       Date:  2008-02       Impact factor: 5.715

7.  Characterization of TMPRSS2:ETV5 and SLC45A3:ETV5 gene fusions in prostate cancer.

Authors:  Beth E Helgeson; Scott A Tomlins; Nameeta Shah; Bharathi Laxman; Qi Cao; John R Prensner; Xuhong Cao; Nirmish Singla; James E Montie; Sooryanarayana Varambally; Rohit Mehra; Arul M Chinnaiyan
Journal:  Cancer Res       Date:  2008-01-01       Impact factor: 12.701

8.  A causal role for ERG in neoplastic transformation of prostate epithelium.

Authors:  Olga Klezovitch; Michael Risk; Ilsa Coleman; Jared M Lucas; Manda Null; Lawrence D True; Peter S Nelson; Valeri Vasioukhin
Journal:  Proc Natl Acad Sci U S A       Date:  2008-02-01       Impact factor: 11.205

9.  Active genes dynamically colocalize to shared sites of ongoing transcription.

Authors:  Cameron S Osborne; Lyubomira Chakalova; Karen E Brown; David Carter; Alice Horton; Emmanuel Debrand; Beatriz Goyenechea; Jennifer A Mitchell; Susana Lopes; Wolf Reik; Peter Fraser
Journal:  Nat Genet       Date:  2004-09-07       Impact factor: 38.330

10.  Cooperativity of TMPRSS2-ERG with PI3-kinase pathway activation in prostate oncogenesis.

Authors:  Jennifer C King; Jin Xu; John Wongvipat; Haley Hieronymus; Brett S Carver; David H Leung; Barry S Taylor; Chris Sander; Robert D Cardiff; Suzana S Couto; William L Gerald; Charles L Sawyers
Journal:  Nat Genet       Date:  2009-04-26       Impact factor: 38.330

View more
  10 in total

1.  Predicting Prostate Cancer Progression as a Function of ETS-related Gene Status, Race, and Obesity in a Longitudinal Patient Cohort.

Authors:  Jennifer Cullen; Denise Young; Yongmei Chen; Michael Degon; James Farrell; Jason Sedarsky; Wagner Baptiste; Philip Rosen; Vladimir Tolstikov; Michael Kiebish; Jacob Kagan; Sudhir Srivastava; Huai-Ching Kuo; Joel T Moncur; Inger L Rosner; Niven Narain; Viatcheslav Akmaev; Gyorgy Petrovics; Albert Dobi; David G McLeod; Shiv Srivastava; Isabell A Sesterhenn
Journal:  Eur Urol Focus       Date:  2017-03-11

2.  Mutational Analysis of Gene Fusions Predicts Novel MHC Class I-Restricted T-Cell Epitopes and Immune Signatures in a Subset of Prostate Cancer.

Authors:  Jennifer L Kalina; David S Neilson; Yen-Yi Lin; Phineas T Hamilton; Alexandra P Comber; Emma M H Loy; S Cenk Sahinalp; Colin C Collins; Faraz Hach; Julian J Lum
Journal:  Clin Cancer Res       Date:  2017-09-27       Impact factor: 12.531

Review 3.  Molecular subtyping of prostate cancer.

Authors:  Samuel D Kaffenberger; Christopher E Barbieri
Journal:  Curr Opin Urol       Date:  2016-05       Impact factor: 2.309

4.  Synergistic Activity with NOTCH Inhibition and Androgen Ablation in ERG-Positive Prostate Cancer Cells.

Authors:  Ahmed A Mohamed; Shyh-Han Tan; Charles P Xavier; Shilpa Katta; Wei Huang; Lakshmi Ravindranath; Muhammad Jamal; Hua Li; Meera Srivastava; Eri S Srivatsan; Taduru L Sreenath; David G McLeod; Alagarsamy Srinivasan; Gyorgy Petrovics; Albert Dobi; Shiv Srivastava
Journal:  Mol Cancer Res       Date:  2017-06-12       Impact factor: 5.852

Review 5.  The role of wild type RAS isoforms in cancer.

Authors:  Bingying Zhou; Channing J Der; Adrienne D Cox
Journal:  Semin Cell Dev Biol       Date:  2016-07-13       Impact factor: 7.727

Review 6.  Clinical variability and molecular heterogeneity in prostate cancer.

Authors:  Jonathan Shoag; Christopher E Barbieri
Journal:  Asian J Androl       Date:  2016 Jul-Aug       Impact factor: 3.285

7.  Decreased TSPAN1 promotes prostate cancer progression and is a marker for early biochemical recurrence after radical prostatectomy.

Authors:  Fan Xu; Yujing Gao; Yanqing Wang; Jiahua Pan; Jianjun Sha; Xiaoguang Shao; Xunlei Kang; Jun Qin; M James You; Yiran Huang; Baijun Dong; Wei Xue
Journal:  Oncotarget       Date:  2016-09-27

Review 8.  Recent advances in prostate cancer research: large-scale genomic analyses reveal novel driver mutations and DNA repair defects.

Authors:  Sander Frank; Peter Nelson; Valeri Vasioukhin
Journal:  F1000Res       Date:  2018-08-02

Review 9.  BRCA Mutations in Prostate Cancer: Assessment, Implications and Treatment Considerations.

Authors:  Sidrah Shah; Rachelle Rachmat; Synthia Enyioma; Aruni Ghose; Antonios Revythis; Stergios Boussios
Journal:  Int J Mol Sci       Date:  2021-11-23       Impact factor: 5.923

10.  TR3 Enhances AR Variant Production and Transactivation, Promoting Androgen Independence of Prostate Cancer Cells.

Authors:  Tuyen Thanh Tran; Keesook Lee
Journal:  Cancers (Basel)       Date:  2022-04-10       Impact factor: 6.575

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.